This ZEB2/LSD1 interaction appears to repress pro-apoptotic genes such as BIM, making ETP-ALL cells susceptible to combined treatment with LSD1 inhibitor and the BCL2 inhibitor ABT-199 or the JAK/STAT inhibitor Ruxolitinib (159). The gene discussed is BCL2; the disease is acute lymphoblastic leukemia.